<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954326</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-95014-002</org_study_id>
    <secondary_id>2020-004894-29</secondary_id>
    <nct_id>NCT04954326</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <acronym>ALL</acronym>
  <official_title>A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Les Laboratoires Servier (L.L.S), Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics (PK) of both lyophilized and&#xD;
      liquid S95014 formulations during the induction phase after a single IV dose in newly&#xD;
      diagnosed paediatric patients with ALL&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">April 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics measurement</measure>
    <time_frame>Day 3 pre-dose just after the infusion,4h after the end of infusion; Day 4: 24h after the end of infusion; Day 5: 48h after the end of infusion; Day 8, Day 10, Day 12, Day 17, Day 21, Day 28</time_frame>
    <description>Area Under the Concentration-Time Curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics measurement</measure>
    <time_frame>Day 3 pre-dose just after the infusion,4h after the end of infusion; Day 4: 24h after the end of infusion; Day 5: 48h after the end of infusion; Day 8, Day 10, Day 12, Day 17, Day 21, Day 28</time_frame>
    <description>Maximum observed plasma asparaginase activity (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics measurements</measure>
    <time_frame>14 days post-dose</time_frame>
    <description>Additional PK parameters from the ones defined as primary endpoint (e.g. Ctrough at 14 days post-dose) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity measurement</measure>
    <time_frame>Day 10, Day 17, Day 21 and Day 28 of induction</time_frame>
    <description>Plasma Asparaginase Activity (PAA) of â‰¥ 0.1 U/mL after the administration of either liquid or lyophilized S95014.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measurements</measure>
    <time_frame>Day 3 pre-dose, Day 17 and Day 28</time_frame>
    <description>Anti S95014 and anti-PEG antibodies will be assessed for both lyophilized and liquid S95014 formulations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (safety and tolerability assessments)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Treatment Emergent Adverse Events (TEAEs) causality and severity based on NCI CTCAE 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Event (safety assessments)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serious Adverse Event (SAEs) causality and severity based on NCI CTCAE 5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>S95014 lyophilizate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S95014 liquid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyophilized S95014</intervention_name>
    <description>Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.&#xD;
Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.</description>
    <arm_group_label>S95014 lyophilizate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liquid S95014</intervention_name>
    <description>Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.&#xD;
Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.</description>
    <arm_group_label>S95014 liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 1 to &lt; 18 years&#xD;
&#xD;
          -  Patients with cytologically confirmed and documented newly diagnosed ALL according to&#xD;
             National Comprehensive Cancer Network guidelines 2020 (see Appendix 2), excluding&#xD;
             B-cell Burkitt ALL&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 (see Appendix 3)&#xD;
&#xD;
          -  Highly effective contraception method&#xD;
&#xD;
          -  Signed informed consent and assent, when appropriate&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Unlikely to cooperate in the study&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Participation in another interventional study at the same time; participation in&#xD;
             non-interventional registries or epidemiological studies is allowed&#xD;
&#xD;
          -  Participant already enrolled in the study (informed consent signed)&#xD;
&#xD;
          -  Women of childbearing potential tested positive in a serum pregnancy test within 7&#xD;
             days prior to the treatment period&#xD;
&#xD;
          -  Inadequate hepatic function (bilirubin &gt; 1.5 times upper limit of normal (ULN),&#xD;
             transaminases &gt; 5x ULN)&#xD;
&#xD;
          -  Inadequate renal function defined as serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  Prior treatment with chemotherapy or radiotherapy (except steroids and intrathecal&#xD;
             therapy)&#xD;
&#xD;
          -  Prior surgery or bone marrow transplant related to the studied disease&#xD;
&#xD;
          -  Down Syndrome&#xD;
&#xD;
          -  Psychiatric illness/social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Known history of pancreatitis&#xD;
&#xD;
          -  Known history of significant liver disease&#xD;
&#xD;
          -  Known carriers of HIV antibodies&#xD;
&#xD;
          -  Significant laboratory abnormality likely to jeopardize the patients' safety or to&#xD;
             interfere with the conduct of the study, in the investigator's opinion&#xD;
&#xD;
          -  Pre-existing known coagulopathy (e.g. haemophilia and known protein S deficiency)&#xD;
&#xD;
          -  History of previous or concurrent malignancy&#xD;
&#xD;
          -  History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs&#xD;
&#xD;
          -  Severe or uncontrolled active acute or chronic infection&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including life-threatening acute tumor lysis&#xD;
             syndrome (e.g. with renal failure), symptomatic congestive heart failure, cardiac&#xD;
             arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Isaakovich Karachunskiy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Institute of Oncology, Radiology and Nuclear Medicine. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier Clinical Studies Department</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinical.trial.management@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regional Children Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Children Clinical Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children Regional Clinical Hospital</name>
      <address>
        <city>Krasnodar</city>
        <zip>350007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian Children Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>119571</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Children Hospital</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>V.A. Almazov National Medical Research Center</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com</url>
    <description>Find results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology / Haematology</keyword>
  <keyword>Phase II</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Parallel group</keyword>
  <keyword>Pegaspargase</keyword>
  <keyword>Pharmacokinetics comparability</keyword>
  <keyword>Lyophilized pegaspargase</keyword>
  <keyword>Liquid pegaspargase</keyword>
  <keyword>Pegaspargase formulation</keyword>
  <keyword>Randomized, open-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

